Journal
ONCOGENE
Volume 30, Issue 19, Pages 2207-2218Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2010.600
Keywords
androgen receptor; androgens; HDAC4; prostate cancer; SUMOylation; SUMO E3 ligase
Funding
- Public Health Service [CA93666, CA111334]
- DOD [DAMD17-02-1-0140]
- Florida Department of Health [09KT-03, 06BCBG1]
Ask authors/readers for more resources
The transcriptional activity of the androgen receptor (AR) is regulated by both ligand binding and post-translational modifications, including acetylation and small ubiquitin-like modifier (SUMO)ylation. Histone deacetylases (HDACs) are known to catalyze the removal of acetyl groups from both histones and non-histone proteins. In this study, we report that HDAC4 binds to and inhibits the activity of the AR. This inhibition was found to depend on the SUMOylation, instead of deacetylation, of the AR. Consistently, HDAC4 increases the level of AR SUMOylation in both whole-cell and cell-free assay systems, raising the possibility that the deacetylase may act as an E3 ligase for AR SUMOylation. Knock down of HDAC4 increases the activity of endogenous AR and androgen induction of prostate-specific antigen expression and prostate cancer cell growth, which is associated with decreased SUMOylation of the receptor. Overall, the studies identify HDAC4 as a positive regulator for AR SUMOylation, revealing a deacetylase-independent mechanism of HDAC action in prostate cancer cells. Oncogene (2011) 30, 2207-2218; doi:10.1038/onc.2010.600; published online 17 January 2011
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available